A proteinogenic amino acid derivative resulting from reaction of L-phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-phenylalanine by a heteroatom.
| Member | Definition | Role |
|---|
| 3-tyrosine | A hydroxyphenylalanine that is L-phenylalanine with a substituent hydroxy group at position 3. | L-m-tyrosine zwitterion; L-m-tyrosine |
| 4-fluorophenyl-L-alanine | A L-phenylalanine derivative that is L-phenylalanine in which the hydrogen at position 4 on the benzene ring is replaced by a fluoro group. | 4-fluorophenyl-L-alanine |
| asperphenamate | A carboxylic ester resulting from the formal condensation of the carboxy group of N-benzoyl-L-phenylalanine with the hydroxy group of N-benzoyl-L-phenylalaninol. A metabolite found in several Pencillium and Aspergillus species, as well as in plants as a product of endophytic fungi. | asperphenamate |
| batimastat | A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor. | batimastat |
| benzyloxycarbonylphenylalanylphenylalanine diazomethyl ketone | A diazo compound that is L-phenylalanyl-L-phenylalanine in which the amino group is protected by a (benzyloxy)carbonyl group and the carboxy group is substituted by a diazoacetyl group. It is a cathepsin L inhibitor. | Z-Phe-Phe-CHN2 |
| bortezomib | L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome. | bortezomib |
| dopaquinone | An L-phenylalanine derivative in which the phenyl group of L-phenylalanine is replaced by a 3,4-dioxocyclohexa-1,5-dien-1-yl group. | L-dopaquinone zwitterion; L-dopaquinone |
| eluxadoline | An amino acid amide obtained by the formal condensation of the carboxy group of 4-carbamoyl-2,6-dimethyl-L-phenylalanine with the secondary amino group of 2-methoxy-5-({[(1S)-1-(4-phenylimidazol-2-yl)ethyl]amino}methyl)benzoic acid. It has mixed opioid receptor activity and is used for treatment of irritable bowel syndrome with diarrhoea. | eluxadoline |
| l796778 | A methyl ester resulting from the formal condensation of the carboxy group of N-{[(2S)-1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-D-norleucyl-L-lysine with methanol. It is a partial agonist of somatostatin subtype receptor 3 (Ki = 24 nM) that exhibits anticonvulsant effects. | L-796,778 |
| melphalan | A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring. | melphalan |
| phenylalanine methyl ester | An alpha-amino acid ester that is the methyl ester of L-phenylalanine. | methyl L-phenylalaninate |
| phenylalanine-beta-naphthylamide | An L-phenylalanine derivative that is the amide obtained by formal condensation of the carboxy group of L-phenylalanine with the amino group of 2-naphthylamine. | L-phenylalanine 2-naphthylamide |
| sar 1118 | An N-acyl-L-alpha-amino acid obtained by formal condensation of the carboxy group of N-[2-(1-benzofuran-6-carbonyl)]-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid with the amino group of 3-(methanesulfonyl)-L-phenylalanine. Used for treatment of keratoconjunctivitis sicca (dry eye syndrome). | lifitegrast |
| thyroxine | The L-enantiomer of thyroxine. | L-thyroxine zwitterion; L-thyroxine |